A Phase II Study to Determine Feasibility and Safety of Single Agent MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma

Trial Profile

A Phase II Study to Determine Feasibility and Safety of Single Agent MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 Status changed from recruiting to suspended for interim analyses.
    • 10 Jun 2017 Biomarkers information updated
    • 25 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top